Form D · Biotechnology
Forte Biosciences, Inc.
Dallas, TX · CIK 0001419041
Offering snapshot reported Aug 9, 2023 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 31, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 9, 2023 | Initial | $25,009,981 | No comparison | 27 | SEC filing |
| Mar 13, 2017 | Amendment | $10,895,750 | $8,160,000vs Dec 6, 2016 | 107 | SEC filing |
| Dec 6, 2016 | Initial | $2,735,750 | No comparison | 17 | SEC filing |
| Oct 22, 2015 | Amendment | $46,200,326 | $17,395,789vs Aug 10, 2015 | 250 | SEC filing |
| Aug 10, 2015 | Amendment | $28,804,537 | $20,294,938vs Jul 3, 2014 | 156 | SEC filing |
| Jul 3, 2014 | Amendment | $8,509,599 | $8,299,599vs Jun 10, 2013 | 77 | SEC filing |
| Jun 10, 2013 | Initial | $210,000 | No comparison | 3 | SEC filing |
| Dec 5, 2012 | Amendment | $9,055,340 | $7,905,340vs Mar 7, 2012 | 32 | SEC filing |
| Mar 7, 2012 | Initial | $1,150,000 | No comparison | 4 | SEC filing |
| Nov 8, 2011 | Amendment | $15,310,930 | $11,590,704vs Feb 16, 2011 | 88 | SEC filing |
| Feb 16, 2011 | Amendment | $3,720,226 | $2,662,224vs Jan 4, 2011 | 33 | SEC filing |
| Jan 4, 2011 | Initial | $1,058,002 | No comparison | 10 | SEC filing |
| Oct 5, 2010 | Amendment | $5,269,000 | $3,134,000vs Jul 23, 2010 | 43 | SEC filing |
| Jul 23, 2010 | Initial | $2,135,000 | No comparison | 24 | SEC filing |
| Mar 5, 2010 | Initial | $7,776,750 | No comparison | 75 | SEC filing |
| Feb 26, 2010 | Initial | $3,000,001 | No comparison | 2 | SEC filing |
| Nov 23, 2009 | Amendment | $9,116,162 | $8,116,162vs Jun 18, 2009 | 100 | SEC filing |
| Jun 18, 2009 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jun 2, 2009 | Amendment | $10,846,000 | No comparison | Not reported | SEC filing |
| May 15, 2009 | Amendment | $10,846,000 | No comparison | Not reported | SEC filing |
| Apr 10, 2009 | Amendment | $7,095,750 | No comparison | Not reported | SEC filing |
| Nov 21, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 12, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 16, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-489206
Source: Form D, filed Aug 9, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Franklin M. Berger | Director |
| Dennis Berman | Director, Executive |
| Scott Brun | Director |
| Hubert Chen | Executive |
| Thomas Darcy | Director, Executive |
| Stephen Doberstein | Director |
| Martin J Duvall | Director, Executive |
| Lawrence Eichenfield | Director |
| Barbara Fink | Director |
| Mark Foletta | Executive |
| Harry Gruber | Director, Executive |
| David Gryska | Director |
| Faheem Hasnain | Director |
| Douglas Jolly | Executive |
| Steven Kornfeld | Director |
| Lori Kunkel | Director |
| David R. Parkinson | Director |
| Antony Riley | Executive |
| Paul R. Schimmel | Director |
| Paul Wagner | Director, Executive |
| Donald Williams | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3060 Pegasus Park Drive Building 6
Dallas, TX, 75247
Dallas, TX, 75247